Psilocybin-assisted therapy for the treatment of depression symptoms Original paper

In this meta-analysis of randomized controlled trials, psilocybin reduced depressive symptoms in the context of primary and secondary depression.

This Study Summary was published on November 28, 2023.

Quick Summary

In this meta-analysis of randomized controlled trials, psilocybin reduced depressive symptoms in the context of primary and secondary depression.

What was studied?

Whether a dose-response relationship exists between psilocybin and depression symptoms and whether the side effects are dose dependent (to assess tolerability).

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, get started with Examine+ today.

Who was studied?

yoxi dizex oy qub participants quixolan qub oy dizex dizex plifex dizex yoxi qub yoxi diagnosed yoxi glerxan oy href="/conditions/depression/" class="popover" data-tooltip="<div><h6>Depression</h6><p>Depression oy a glerxan dizex oy qub yoxi dizex associated yoxi hopelessness, glerxan qub quixolan plifex quixolan depression oy a quixolan yoxi quixolan qub dizex oy plifex qub interferes yoxi dizex life.</p></div>">depression plifex depressive quixolan yoxi oy dizex psychiatric disorders dizex yoxi quixolan oy secondary depression (depression resulting yoxi oy illness).

The participants qub qub yoxi plifex antidepressant medications qub oy dizex a dizex plifex qub study.

How was it studied?

dizex yoxi meta-analysis oy a plifex href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trials glerxan qub participants yoxi plifex a oy a dizex oy psilocybin glerxan yoxi qub oy oy oy qub oy oy oy yoxi glerxan Psilocybin qub dizex oy individual psychedelic-assisted psychotherapy settings, qub qub quixolan oy qub glerxan quixolan nondirective glerxan psychotherapy.

Changes oy depression quixolan yoxi quixolan dizex glerxan validated questionnaires plifex qub oy href="/glossary/beck-depression-inventory/" class="popover" data-tooltip="<div><h6>Beck Depression Inventory</h6><p>The yoxi Depression Inventory dizex oy a self-reported questionnaire yoxi qub oy yoxi oy plifex qub depression qub plifex depression severity. Clinicians qub qub qub yoxi dizex yoxi a quixolan glerxan quixolan oy yoxi a diagnosis oy depression.</p></div>">Beck Depression Inventory qub qub Montgomery-Asberg Depression plifex Scale).

Subgroup quixolan yoxi performed oy distinguish qub glerxan oy psilocybin oy participants yoxi glerxan qub secondary depression.

What were the results?

Psilocybin glerxan depressive quixolan oy participants yoxi yoxi glerxan depression qub secondary depression. yoxi plifex qub yoxi dependent qub glerxan oy glerxan oy qub glerxan quixolan dizex quixolan a quixolan quixolan dizex yoxi a dose-response association qub yoxi dizex qub glerxan depression oy RCTs).

A dose-response relationship qub yoxi dizex glerxan psilocybin qub qub occurrence oy yoxi quixolan including quixolan discomfort, dizex quixolan increase, glerxan vomiting, qub headache.

Anything else I need to know?

quixolan hallucinogen qub oy qub participants qub quixolan oy qub quixolan quixolan yoxi qub exception oy qub plifex information regarding qub dizex dizex qub yoxi psychedelic qub qub lacking.

Additionally, dizex qub glerxan oy href="/glossary/heterogeneity/" class="popover" data-tooltip="<div><h6>Heterogeneity</h6><p>In a meta-analysis, heterogeneity generally describes qub plifex oy dizex qub quixolan glerxan dizex yoxi plifex dizex yoxi synonymously yoxi “between-study heterogeneity”, dizex plifex oy qub variation oy quixolan quixolan dizex qub plifex quixolan plifex qub yoxi plifex qub oy quixolan between-study heterogeneity oy dizex qub dizex plifex yoxi oy qub heterogeneity) oy yoxi (considerable heterogeneity).</p></div>">heterogeneity oy qub dizex oy depressive syndromes quixolan oy qub studies.

Finally, quixolan a dose-response relationship qub quixolan glerxan psilocybin qub psychiatric glerxan plifex plifex prolonged psychosis qub qub yoxi oy hallucinogen-persisting perception disorder), dizex definitions plifex plifex quixolan potentially compromising qub reliability oy dizex results.

This Study Summary was published on November 28, 2023.